A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
Takeda
Takeda
University Hospital, Toulouse
University Hospital, Toulouse
H. Lee Moffitt Cancer Center and Research Institute
Brown University
Stichting Hemato-Oncologie voor Volwassenen Nederland
Alliance Foundation Trials, LLC.
Pfizer
Centre Hospitalier Régional d'Orléans
Hospices Civils de Lyon
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Institut Curie
University of Chicago
University of Rochester
University Hospital, Grenoble
Case Comprehensive Cancer Center
Thomas Jefferson University
Hospital Universitario Dr. Jose E. Gonzalez
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Emory University
UNC Lineberger Comprehensive Cancer Center
University of Rochester
Wake Forest University Health Sciences
Peter MacCallum Cancer Centre, Australia
Advice Pharma Group srl
Rush University Medical Center
University Hospital, Toulouse
Astex Pharmaceuticals, Inc.
Juno Therapeutics, a Subsidiary of Celgene
M.D. Anderson Cancer Center
Amsterdam UMC, location VUmc
Kyowa Kirin Co., Ltd.
National Cancer Institute (NCI)
University of Leeds
University of Nebraska
Canadian Cancer Trials Group
European Society for Blood and Marrow Transplantation
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Insel Gruppe AG, University Hospital Bern
Virginia Commonwealth University
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Amgen